Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.


All ideas
are listed as non-confidential technical summaries.

Ideas were generated by academic institutions, entrepreneurs, and corporations.

Ideas from our research institution partners can be reviewed by following the web links to their database.

Highlighted ideas from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available..

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Preventing Herpes Simplex Virus Replication with a New Class of Drugs

Researchers at Saint Louis University have developed new derivatives of an N-hydroxypryidinone molecule that act as inhibitors of herpes simplex virus replication. Research is at the hit to lead optimization stage.
Herpes simplex viruses (HSV) are members of the human Herpesviridae family. HSV is categorized into two types, both of which are common and contagious. Worldwide an estimated 3.7 billion people under age 50 are infected with HSV-1 and about 417 million people ages 15-49 are infected with HSV-2. Currently available treatments do not cure HSV infections. Additionally, drug resistance is problematic with certain HSV patient populations.

Benefits
 

The potential advantages of this technology over existing solutions include:

  • Minimizing the need for recurring treatment.
  • Increasing the effectiveness of treatments.
  • Minimizing drug resistance.
  • Minimizing toxicity of treatments.

    Applications
     

    Potential applications of this technology include treating and curing herpes simplex virus infections.

Additional Details

Owner

St. Louis University

Intellectual Property Protection

Pending Patent



Interested? Request More Information